ATE255905T1 - Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält - Google Patents
Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthältInfo
- Publication number
- ATE255905T1 ATE255905T1 AT97905541T AT97905541T ATE255905T1 AT E255905 T1 ATE255905 T1 AT E255905T1 AT 97905541 T AT97905541 T AT 97905541T AT 97905541 T AT97905541 T AT 97905541T AT E255905 T1 ATE255905 T1 AT E255905T1
- Authority
- AT
- Austria
- Prior art keywords
- iscom
- mucosa
- antigen
- active ingredient
- matrix
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 210000004877 mucosa Anatomy 0.000 title 1
- 230000002163 immunogen Effects 0.000 abstract 2
- 210000004400 mucous membrane Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 229930182470 glycoside Natural products 0.000 abstract 1
- 150000002338 glycosides Chemical class 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 210000003563 lymphoid tissue Anatomy 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000010415 tropism Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600647A SE9600647D0 (sv) | 1996-02-21 | 1996-02-21 | Ny användning |
| PCT/SE1997/000289 WO1997030728A1 (en) | 1996-02-21 | 1997-02-20 | Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE255905T1 true ATE255905T1 (de) | 2003-12-15 |
Family
ID=20401481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97905541T ATE255905T1 (de) | 1996-02-21 | 1997-02-20 | Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6607732B2 (de) |
| EP (1) | EP0889736B1 (de) |
| JP (1) | JP2000504746A (de) |
| AT (1) | ATE255905T1 (de) |
| AU (1) | AU719084B2 (de) |
| CA (1) | CA2247522C (de) |
| DE (1) | DE69726712T2 (de) |
| DK (1) | DK0889736T3 (de) |
| ES (1) | ES2210495T3 (de) |
| NZ (1) | NZ331403A (de) |
| SE (1) | SE9600647D0 (de) |
| WO (1) | WO1997030728A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DK1077722T3 (da) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Fremgangsmåder og produkter til induktion af mukosaimmunitet |
| US7041296B1 (en) * | 1999-11-12 | 2006-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of treating inflammatory bowel disease using cholera toxin B subunit |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| ES2433467T3 (es) | 2005-01-20 | 2013-12-11 | Isconova Ab | Composición de vacuna que comprende una proteína de unión a fibronectina o un péptido de unión a fibronectina |
| CA2698392C (en) | 2007-09-04 | 2019-12-03 | Baoming Jiang | Thermal inactivation of rotavirus |
| GB0803076D0 (en) | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
| ES2325243B1 (es) * | 2008-02-27 | 2011-05-04 | Universidad De Granada | Antigeno recombinante. |
| ES2987238T3 (es) | 2008-12-09 | 2024-11-14 | Novavax Inc | Proteínas F del RSV modificadas y métodos de su uso |
| CA2805741C (en) | 2010-07-23 | 2019-08-13 | Karin Bengtsson Loevgren | Composition including an iscom matrix and ectodomains |
| ES2639122T3 (es) | 2011-05-13 | 2017-10-25 | Zoetis Services Llc | Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah |
| DK2750683T4 (da) | 2011-10-03 | 2021-04-12 | Croda Int Plc | Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser |
| EP4272750A3 (de) | 2013-02-07 | 2024-01-24 | Children's Medical Center, Corp. | Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall |
| WO2014163558A1 (en) | 2013-04-01 | 2014-10-09 | Moreinx Ab | Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds |
| EP3082856A1 (de) | 2013-12-16 | 2016-10-26 | Zoetis Services LLC | Immunogene hendra- und nipah-virus-g-glycoprotein-zusammensetzungen |
| CN114617959A (zh) | 2015-09-03 | 2022-06-14 | 诺瓦瓦克斯股份有限公司 | 具有改进的稳定性和免疫原性的疫苗组合物 |
| CN111148509A (zh) | 2017-07-24 | 2020-05-12 | 诺瓦瓦克斯股份有限公司 | 治疗呼吸系统疾病的方法和组合物 |
| CN120227451A (zh) | 2018-03-19 | 2025-07-01 | 诺瓦瓦克斯股份有限公司 | 多价流感纳米颗粒疫苗 |
| AU2021214064A1 (en) | 2020-01-27 | 2022-08-18 | Novavax, Inc. | Coronavirus vaccine formulations |
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| JP2024516309A (ja) | 2021-05-05 | 2024-04-12 | ノババックス，インコーポレイテッド | コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 |
| GB202209588D0 (en) | 2022-06-29 | 2022-08-10 | Plant Bioscience Ltd | Methods and compositions |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6290962B1 (en) * | 1992-11-03 | 2001-09-18 | Oravax, Inc. | Urease-based vaccine and treatment for helicobacter infection |
-
1996
- 1996-02-21 SE SE9600647A patent/SE9600647D0/xx unknown
-
1997
- 1997-02-20 JP JP9530070A patent/JP2000504746A/ja active Pending
- 1997-02-20 AT AT97905541T patent/ATE255905T1/de not_active IP Right Cessation
- 1997-02-20 AU AU22385/97A patent/AU719084B2/en not_active Expired
- 1997-02-20 CA CA002247522A patent/CA2247522C/en not_active Expired - Lifetime
- 1997-02-20 EP EP97905541A patent/EP0889736B1/de not_active Expired - Lifetime
- 1997-02-20 ES ES97905541T patent/ES2210495T3/es not_active Expired - Lifetime
- 1997-02-20 NZ NZ331403A patent/NZ331403A/en not_active IP Right Cessation
- 1997-02-20 DK DK97905541T patent/DK0889736T3/da active
- 1997-02-20 DE DE69726712T patent/DE69726712T2/de not_active Expired - Lifetime
- 1997-02-20 WO PCT/SE1997/000289 patent/WO1997030728A1/en not_active Ceased
-
1998
- 1998-08-20 US US09/137,236 patent/US6607732B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2000504746A (ja) | 2000-04-18 |
| EP0889736B1 (de) | 2003-12-10 |
| US20020131982A1 (en) | 2002-09-19 |
| CA2247522C (en) | 2009-12-29 |
| DE69726712T2 (de) | 2004-10-07 |
| AU2238597A (en) | 1997-09-10 |
| WO1997030728A1 (en) | 1997-08-28 |
| CA2247522A1 (en) | 1997-08-28 |
| NZ331403A (en) | 2000-02-28 |
| DE69726712D1 (de) | 2004-01-22 |
| DK0889736T3 (da) | 2004-04-19 |
| EP0889736A1 (de) | 1999-01-13 |
| US6607732B2 (en) | 2003-08-19 |
| AU719084B2 (en) | 2000-05-04 |
| SE9600647D0 (sv) | 1996-02-21 |
| ES2210495T3 (es) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69726712D1 (de) | Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält | |
| IL130931A0 (en) | Small molecules useful in the treatment of inflammatory disease | |
| IS5329A (is) | Flutningskerfi fyrir antígen þar sem monoglýseríðeða díglýseríð afleiður eru ónæmisglæðar | |
| ES2196024T3 (es) | Vacunas conjugadas de gangliosido-klh con qs-21. | |
| NO20101067L (no) | Hydroksymatairesinol i forhindring av kreft | |
| ITFI920058A1 (it) | Composti coniugati formati da proteine heat shock (hsp) e oligo-polisaccaridi, loro uso per la produzione di vaccini. | |
| ES2134797T3 (es) | Peptidos y fragmentos de peptidos terapeuticamente utiles. | |
| CY1107838T1 (el) | Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων | |
| ES2157447T3 (es) | Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio. | |
| MX9203808A (es) | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. | |
| NO991524L (no) | Vaksiner | |
| DE69524389D1 (de) | 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung | |
| ITFI920052A0 (it) | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
| AR030829A1 (es) | Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal | |
| NO992102L (no) | Peptidblanding, samt farmasøytisk sammensetning og kreftvaksine som innbefatter peptidblandingen | |
| FI956014A0 (fi) | Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon | |
| DZ2283A1 (fr) | Composition de vaccin. | |
| BR9610679A (pt) | Antígenos de leishmania para uso na terapia e disgnose da leishmaniose | |
| DK1024824T3 (da) | Dispergerende vaccinesammensætning i fast form til oral indgivelse | |
| NO972219D0 (no) | Immunogenpreparater | |
| TR28331A (tr) | 13-ikameli milbemisin türevleri, bunlarin hazirlanmalari ve kullanimlari. | |
| WO1997026867A3 (de) | Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung | |
| WO2000003724A1 (en) | Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient | |
| FI894650L (fi) | Antigen, som associerar till en human tumoer. | |
| WO2001034185A3 (en) | Induction of mucosal immunity by vaccination via the skin route |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0889736 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |